Saint-Herblain, France — November 26, 2025 — Leads & Copy —
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced a strategic initiative to optimize its organizational footprint in France. The company plans to concentrate its French operations at its Lyon location, closing the site in Nantes. This consolidation will streamline operations and improve efficiency in France, while also centralizing all Research and Development activities at the Company’s site in Vienna.
The company plans to relocate its registered office back to Lyon, where it was originally established, and maintain its listing on Euronext Paris. The city of Lyon in France is internationally recognized as a leading vaccine hub, home to major players such as Sanofi Pasteur and the Mérieux group, making it an ideal location for Valneva to concentrate its French operations.
Valneva is committed to supporting employees throughout this transition and providing assistance to ensure a smooth process for all impacted team members.
Valneva SE develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company takes a specialized and targeted approach, applying its expertise across multiple vaccine modalities, focused on providing vaccine solutions. Valneva currently markets three proprietary travel vaccines.
Revenues from Valneva’s growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes a Lyme disease vaccine candidate in advanced clinical development, partnered with Pfizer, and a Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Laetitia Bachelot-Fontaine, VP, Global Communications and European Investor Relations, can be reached at +33 (0)6 4516 7099 or laetitia.bachelotfontaine@valneva.com. Joshua Drumm, Ph.D., VP, Global Investor Relations, can be reached at +001 917 815 4520 or joshua.drumm@valneva.com.
Source: Valneva SE
